Research location
Harfleur
France
Advertisement
Research activity in Harfleur
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Harfleur
9 linked trials · page 1 of 1Paclitaxel-bevacizumab in Advanced Lung CancerNCT01763671 · 2013-05-01 · 1 site observation
COMPLETED
Bevacizumab in Extensive Small Cell Lung CancerNCT00930891 · 2009-09-01 · 1 site observation
COMPLETED
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational StudyNCT00909038 · 2009-05-01 · 1 site observation
COMPLETED
National Survey on Coronary Patients and Heart Failure Performed in 2 Patient GroupsNCT00699959 · 2008-06-01 · 1 site observation
COMPLETED
A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on DialysisNCT02827266 · 2005-10-01 · 1 site observation
COMPLETED
Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung CancerNCT00274898 · 2004-05-01 · 1 site observation
UNKNOWN
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast CancerNCT00053911 · 2002-11-01 · 1 site observation
TERMINATED
Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung CancerNCT00077220 · 2002-06-01 · 1 site observation
UNKNOWN
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerNCT00054587 · 2001-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.